Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + 5-FU/LV vs capecitabine as adjuvant therapy in high-risk resectable biliary tract malignancies
ChiCTR2500107091Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of irinotecan liposome, fluorouracil, folinic acid and capecitabine in biliary cancer (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: overall survival and recurrence-free survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomefluorouracilfolinic acidcapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500107091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107091.